These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
335 related articles for article (PubMed ID: 28856744)
1. Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma. Zheng M; Perry AM; Bierman P; Loberiza F; Nasr MR; Szwajcer D; Del Bigio MR; Smith LM; Zhang W; Greiner TC Neuropathology; 2017 Dec; 37(6):509-516. PubMed ID: 28856744 [TBL] [Abstract][Full Text] [Related]
2. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma. Takeuchi T; Yamaguchi M; Kobayashi K; Miyazaki K; Tawara I; Imai H; Ono R; Nosaka T; Tanaka K; Katayama N Cancer; 2017 Apr; 123(7):1166-1173. PubMed ID: 27915469 [TBL] [Abstract][Full Text] [Related]
3. Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma. Taniguchi K; Takata K; Chuang SS; Miyata-Takata T; Sato Y; Satou A; Hashimoto Y; Tamura M; Nagakita K; Ohnishi N; Noujima-Harada M; Tabata T; Kikuti YY; Maeda Y; Nakamura N; Tanimoto M; Yoshino T Am J Surg Pathol; 2016 Mar; 40(3):324-34. PubMed ID: 26752547 [TBL] [Abstract][Full Text] [Related]
4. Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations. Yamada S; Ishida Y; Matsuno A; Yamazaki K Leuk Lymphoma; 2015 Jul; 56(7):2141-5. PubMed ID: 25347427 [TBL] [Abstract][Full Text] [Related]
5. Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations. Cao XX; Li J; Cai H; Zhang W; Duan MH; Zhou DB Ann Hematol; 2017 Nov; 96(11):1867-1871. PubMed ID: 28803429 [TBL] [Abstract][Full Text] [Related]
6. Morphologic Patterns and the Correlation With MYD88 L265P, CD79B Mutations in Primary Adrenal Diffuse Large B-Cell Lymphoma. Chen Z; Zou Y; Liu W; Guan P; Tao Q; Xiang C; Zhang W; Ye Y; Yan J; Zhao S Am J Surg Pathol; 2020 Apr; 44(4):444-455. PubMed ID: 31609782 [TBL] [Abstract][Full Text] [Related]
7. CD79B and MYD88 mutations in diffuse large B-cell lymphoma. Kim Y; Ju H; Kim DH; Yoo HY; Kim SJ; Kim WS; Ko YH Hum Pathol; 2014 Mar; 45(3):556-64. PubMed ID: 24444466 [TBL] [Abstract][Full Text] [Related]
8. MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma. Aggarwal V; Das A; Bal A; Srinivasan R; Das R; Prakash G; Malhotra P; Varma S Appl Immunohistochem Mol Morphol; 2019 Apr; 27(4):311-318. PubMed ID: 29734251 [TBL] [Abstract][Full Text] [Related]
9. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. Nakamura T; Tateishi K; Niwa T; Matsushita Y; Tamura K; Kinoshita M; Tanaka K; Fukushima S; Takami H; Arita H; Kubo A; Shuto T; Ohno M; Miyakita Y; Kocialkowski S; Sasayama T; Hashimoto N; Maehara T; Shibui S; Ushijima T; Kawahara N; Narita Y; Ichimura K Neuropathol Appl Neurobiol; 2016 Apr; 42(3):279-90. PubMed ID: 26111727 [TBL] [Abstract][Full Text] [Related]
10. Nomogram for predicting survival of patients with diffuse large B-cell lymphoma. Fujii K; Inagaki A; Masaki A; Sugiura M; Suzuki T; Ishida T; Kusumoto S; Iida S; Inagaki H Ann Hematol; 2024 Jun; 103(6):2041-2050. PubMed ID: 38411628 [TBL] [Abstract][Full Text] [Related]
11. CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in primary central nervous system lymphoma. Yamaguchi J; Ohka F; Lushun C; Motomura K; Aoki K; Takeuchi K; Nagata Y; Ito S; Mizutani N; Ohno M; Suzaki N; Takasu S; Seki Y; Kano T; Wakabayashi K; Oyama H; Kurahashi S; Tanahashi K; Hirano M; Shimizu H; Kitano Y; Maeda S; Yamazaki S; Wakabayashi T; Kondo Y; Natsume A; Saito R Cancer Med; 2023 Mar; 12(6):7116-7126. PubMed ID: 36478416 [TBL] [Abstract][Full Text] [Related]
12. Mutational frequencies of CD79B and MYD88 vary greatly between primary testicular DLBCL and gastrointestinal DLBCL. Frick M; Bettstetter M; Bertz S; Schwarz-Furlan S; Hartmann A; Richter T; Lenze D; Hummel M; Dreyling M; Lenz G; Gaumann A Leuk Lymphoma; 2018 May; 59(5):1260-1263. PubMed ID: 28868954 [No Abstract] [Full Text] [Related]
13. Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases. Dubois S; Viailly PJ; Bohers E; Bertrand P; Ruminy P; Marchand V; Maingonnat C; Mareschal S; Picquenot JM; Penther D; Jais JP; Tesson B; Peyrouze P; Figeac M; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Fabiani B; Delarue R; Peyrade F; André M; Ketterer N; Leroy K; Salles G; Molina TJ; Tilly H; Jardin F Clin Cancer Res; 2017 May; 23(9):2232-2244. PubMed ID: 27923841 [No Abstract] [Full Text] [Related]
14. MGMT methylation in diffuse large B-cell lymphoma: validation of quantitative methylation-specific PCR and comparison with MGMT protein expression. Uccella S; Cerutti R; Placidi C; Marchet S; Carnevali I; Bernasconi B; Proserpio I; Pinotti G; Tibiletti MG; Furlan D; Capella C J Clin Pathol; 2009 Aug; 62(8):715-23. PubMed ID: 19638543 [TBL] [Abstract][Full Text] [Related]
15. Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes. Xie Z; Qin Y; Chen X; Yang S; Yang J; Gui L; Liu P; He X; Zhou S; Zhang C; Tang L; Shi Y Target Oncol; 2024 May; 19(3):383-400. PubMed ID: 38643457 [TBL] [Abstract][Full Text] [Related]
16. CD79B mutations in primary vitreoretinal lymphoma: Diagnostic and prognostic potential. Yonese I; Takase H; Yoshimori M; Onozawa E; Tsuzura A; Miki T; Mochizuki M; Miura O; Arai A Eur J Haematol; 2019 Feb; 102(2):191-196. PubMed ID: 30390359 [TBL] [Abstract][Full Text] [Related]
17. Comparative Study on the Clinicopathologic and Molecular Characteristics of Primary and Secondary Diffuse Large B-cell Lymphoma in the Central Nervous System. DO J; Yenwongfai LN; DO SI; Kim SW; Na K Anticancer Res; 2024 Jul; 44(7):2953-2960. PubMed ID: 38925823 [TBL] [Abstract][Full Text] [Related]
18. Detection of circulating tumor DNA in plasma of patients with primary CNS lymphoma by digital droplet PCR. Zhong Y; Tan GW; Bult J; Veltmaat N; Plattel W; Kluiver J; Enting R; Diepstra A; van den Berg A; Nijland M BMC Cancer; 2024 Apr; 24(1):407. PubMed ID: 38566053 [TBL] [Abstract][Full Text] [Related]
19. [MGMT expression in primary central nervous system diffuse large B cell lymphoma and its relationship with prognosis]. Shi QY; Feng X; Wang JJ; Wang X; Bao W; Ma J; Shi QL Zhonghua Bing Li Xue Za Zhi; 2016 Dec; 45(12):850-853. PubMed ID: 28056300 [No Abstract] [Full Text] [Related]
20. Clonal Evolution in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System. Garcia-Reyero J; Martinez Magunacelaya N; Gonzalez Pereña A; Marcos Gonzalez S; Teran-Villagra N; Azueta A; Batlle A; Gonzalez de Villambrosia S; Revert Arce J; Montes-Moreno S Appl Immunohistochem Mol Morphol; 2020 Sep; 28(8):e68-e71. PubMed ID: 29629945 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]